CSIMarket Company Name, Ticker, Customers, else..
 
Pressure Biosciences Inc   (PBIO)
Other Ticker:  
 
 
Price: $0.0127 $0.00 1.600%
Day's High: $0.0127 Week Perf: 10.43 %
Day's Low: $ 0.01 30 Day Perf: 154 %
Volume (M): 10 52 Wk High: $ 0.31
Volume (M$): $ 0 52 Wk Avg: $0.10
Open: $0.01 52 Wk Low: $0.00



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 40
 Employees 11
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -37
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Pressure Biosciences Inc
Pressure Biosciences Inc. is a life sciences company that develops and markets innovative technologies and products for the life science and other industries. The company is primarily focused on the development and commercialization of the proprietary Pressure Cycling Technology (PCT) platform, which uses alternating cycles of hydrostatic pressure to control biomolecular interactions. This technology has a wide range of applications, including sample preparation for next-generation DNA sequencing, protein extraction from cells and tissues, and the development of biomarkers for medical diagnostics. Pressure Biosciences Inc. aims to provide researchers with high-quality, innovative solutions for their sample preparation needs, ultimately driving advancements in various scientific fields.


   Company Address: 440 Neponset Street Canton 2021 MA
   Company Phone Number: 230-1828   Stock Exchange / Ticker: PBIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
A   -0.59%    
AVTR   -5.67%    
BIO        2.7% 
BRKR   -3.02%    
ILMN   -0.43%    
MTD   -4.96%    
• View Complete Report
   



Pressure Biosciences Inc

Pressure Biosciences Inc Reports Mixed Financial Results for Q2 2023, with Modest Revenue Growth



Pressure Biosciences Inc's (PBIO) financial results for the second quarter of 2023 have left analysts and investors with mixed emotions. While the company reported a surge in net deficit and a decline in inventories and accounts receivable, they managed to achieve modest revenue growth. This article will analyze PBIO's financial performance in the context of the overall Laboratory Analytical Instruments industry and the company's stock performance.
Financial Results Analysis:
PBIO reported a per-share deficit of $-0.57 for the second quarter of 2023, an increase from -$0.32 in the same quarter a year ago. Sequentially, the deficit also rose from -$0.46 per share from the prior quarter. This decline in profitability raises concerns among investors and underscores the need for PBIO to address its financial challenges.






Pressure Biosciences Inc's Segments
Hardware    23.76 % of total Revenue
Consumables    10.88 % of total Revenue
Sample Preparation Accessories    13.74 % of total Revenue
Consumer Products    44.09 % of total Revenue
Technical Support Extended Service Contracts    5.73 % of total Revenue
Shipping and Handling    1.72 % of total Revenue
Transferred at a Point In Time    93.91 % of total Revenue
Transferred Over At Time    6.01 % of total Revenue
North America    97.35 % of total Revenue
Europe    1.72 % of total Revenue
Asia    0.86 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com